Industry News
Biotechnology Industry News
Goldfinch’s phase 2 kidney disease therapy scores in one indication, misses in another
Goldfinch's phase 2 kidney disease therapy scores in one indication, misses in another mbayer Mon, 02/28/2022 - 02:20
Biohaven to take a chance on Bristol Myers’ once-failed DMD med
Biohaven to take a chance on Bristol Myers' once-failed DMD med mbayer Fri, 02/25/2022 - 10:50
MacroGenics switches horses in CD123 race, canning flotetuzumab in favor of next-gen successor
MacroGenics switches horses in CD123 race, canning flotetuzumab in favor of next-gen successor ntaylor Fri, 02/25/2022 - 06:39
Shionogi files for approval of oral COVID-19 antiviral in Japan, brushing off missed clinical endpoint in race to market
Shionogi files for approval of oral COVID-19 antiviral in Japan, brushing off missed clinical endpoint in race to market ntaylor Fri, 02/25/2022 - 05:49
Russian invasion of Ukraine could affect more than 200 clinical trials across biotech and pharma
Russian invasion of Ukraine could affect more than 200 clinical trials across biotech and pharma klahucik Thu, 02/24/2022 - 14:51
UPDATED: Biotech leaders call on industry to cut ties with Russia amid Ukraine invasion
UPDATED: Biotech leaders call on industry to cut ties with Russia amid Ukraine invasion klahucik Thu, 02/24/2022 - 14:51
AbbVie ditches fibrosis program it paid Morphic $20M for in 2020
AbbVie ditches fibrosis program it paid Morphic $20M for in 2020 klahucik Thu, 02/24/2022 - 12:46
Chutes & Ladders—A new Spark, in CEO form, at Roche’s gene therapy biotech
Chutes & Ladders—A new Spark, in CEO form, at Roche's gene therapy biotech klahucik Thu, 02/24/2022 - 11:45
Takeda, Arch back hC Bioscience with $24M for transfer RNAs, following Flagship into the field
Takeda, Arch back hC Bioscience with $24M for transfer RNAs, following Flagship into the field klahucik Thu, 02/24/2022 - 11:01
Orphazyme goes soul searching as EU advisers add 2nd rejection for rare disease drug
Orphazyme goes soul searching as EU advisers add 2nd rejection for rare disease drug klahucik Thu, 02/24/2022 - 09:28
Merck cuts ties to Moderna’s early-phase KRAS vaccine, leaving mRNA specialist to mull next steps
Merck cuts ties to Moderna's early-phase KRAS vaccine, leaving mRNA specialist to mull next steps ntaylor Thu, 02/24/2022 - 08:52
Amicus’ gene therapy SPAC merger folds, turning pipeline and R&D into target of $400M in cuts
Amicus' gene therapy SPAC merger folds, turning pipeline and R&D into target of $400M in cuts ntaylor Thu, 02/24/2022 - 07:51
Mnemo lures Bayer oncology business chief as new CEO to lead CAR-T work
Mnemo lures Bayer oncology business chief as new CEO to lead CAR-T work mbayer Wed, 02/23/2022 - 10:31
Kodiak’s Eylea rival hits ‘major disappointment’ with failure in first of 6 phase 3 studies
Kodiak's Eylea rival hits 'major disappointment' with failure in first of 6 phase 3 studies klahucik Wed, 02/23/2022 - 09:04
Sanofi, GSK post 58% efficacy in omicron-affected COVID-19 vaccine trial, teeing up race to regulators
Sanofi, GSK post 58% efficacy in omicron-affected COVID-19 vaccine trial, teeing up race to regulators ntaylor Wed, 02/23/2022 - 07:39
Stability woes torpedo Marinus’ phase 3 seizure timeline, combining with COVID-19 to cause one-year delay
Stability woes torpedo Marinus' phase 3 seizure timeline, combining with COVID-19 to cause one-year delay ntaylor Wed, 02/23/2022 - 05:04
Roche’s gene therapy unit finds a new Spark as co-founding CEO makes way for new leader
Roche's gene therapy unit finds a new Spark as co-founding CEO makes way for new leader klahucik Tue, 02/22/2022 - 23:45
‘Better than Abecma’: Slimmed-down 2seventy charts own course after bluebird split
'Better than Abecma': Slimmed-down 2seventy charts own course after bluebird split mbayer Tue, 02/22/2022 - 18:34
Poseida taps former Novartis VP as president of gene therapy
Poseida taps former Novartis VP as president of gene therapy mbayer Tue, 02/22/2022 - 15:09
Plexium nabs $102M for protein degradation work weeks after $500M Amgen tie-up
Plexium nabs $102M for protein degradation work weeks after $500M Amgen tie-up klahucik Tue, 02/22/2022 - 11:44